Patents by Inventor Calum Macleod

Calum Macleod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiophene derivatives as antiviral agents
    Patent number: 11807618
    Abstract: The present invention relates to a new class of compounds having an antiviral effect and the uses thereof.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: November 7, 2023
    Assignee: ENYO PHARMA
    Inventors: Eric Meldrum, Benoît De Chassey, Laëtitia Lines, Jérôme Amaudrut, Benaissa Boubia, Vincent Derain, Fabrice Guillier, Christian Montalbetti, Calum Macleod, Karine Fabienne Malagu, David Robert Vesey, Paul Colin Michael Winship
  • Benzoxazepin oxazolidinone compounds and methods of use
    Patent number: 11760753
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: September 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
  • Fused thiophene derivatives and their uses
    Patent number: 11603368
    Abstract: The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: March 14, 2023
    Assignee: ENYO PHARMA
    Inventors: Eric Meldrum, Benoît De Chassey, Peter Machin, Roberta Lanaro, Calum Macleod, Karine Fabienne Malagu, Nicolas Proisy, David Robert Vesey, Paul Colin Michael Winship, Mark Chambers, Jean-Laurent Paparin
  • Fused thiophene derivatives and their uses
    Patent number: 11492347
    Abstract: The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 8, 2022
    Assignee: ENYO PHARMA
    Inventors: Eric Meldrum, Benoît De Chassey, Peter Machin, Roberta Lanaro, Calum MacLeod, Karine Fabienne Malagu, Nicolas Proisy, David Robert Vesey, Paul Colin Michael Winship, Mark Chambers
  • COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
    Publication number: 20220289751
    Abstract: The compound disclosed is a KDM5 inhibitor represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification, or a salt thereof, and is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.
    Type: Application
    Filed: July 16, 2020
    Publication date: September 15, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akito KAKUUCHI, Shuhei UMEMURA, Mats SVENSSON, Anatoly RUVINSKY, Daigo INOYAMA, Goran KRILOV, Hidenori TAKAHASHI, Kyle KONZE, Andreas VERRAS, Simon CRUMPLER, Maelle VALLADE, Calum MACLEOD, James N. SANDERSON, Richard J. BULL, Simon GAINES
  • THIOPHENE DERIVATIVES AS ANTIVIRAL AGENTS
    Publication number: 20220213053
    Abstract: The present invention relates to a new class of compounds having an antiviral effect and the uses thereof.
    Type: Application
    Filed: March 18, 2022
    Publication date: July 7, 2022
    Inventors: ERIC MELDRUM, BENOÎT DE CHASSEY, LAËTITIA LINES, JÉRÔME AMAUDRUT, BENAISSA BOUBIA, VINCENT DERAIN, FABRICE GUILLIER, CHRISTIAN MONTALBETTI, CALUM MACLEOD, KARINE FABIENNE MALAGU, DAVID ROBERT VESEY, PAUL COLIN MICHAEL WINSHIP
  • Thiophene derivatives as antiviral agents
    Patent number: 11279683
    Abstract: The present invention relates to a new class of compounds of formula (I) having an antiviral effect and the uses thereof.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: March 22, 2022
    Assignee: ENYO PHARMA
    Inventors: Eric Meldrum, Benoit De Chassey, Laetitia Lines, Jerome Amaudrut, Benaissa Boubia, Vincent Derain, Fabrice Guillier, Christian Montalbetti, Calum MacLeod, Karine Fabienne Malagu, David Robert Vesey, Paul Colin Michael Winship
  • Substituted azaindoline derivatives as NIK inhibitors
    Patent number: 11236084
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: February 1, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: George Hynd, Calum Macleod, Samuel Edward Mann, Janusz Jozef Kulagowski, Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel
  • Cyanoindoline derivatives as NIK inhibitors
    Patent number: 11186589
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 30, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Substituted cyanoindoline derivatives as NIK inhibitors
    Patent number: 11180487
    Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: November 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
  • Heteroaromatic derivatives as NIK inhibitors
    Patent number: 11136311
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 5, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
    Publication number: 20210246129
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: October 20, 2020
    Publication date: August 12, 2021
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle BRAUN, Emily HANAN, Steven T. STABEN, Robert Andrew HEALD, Calum MACLEOD, Richard ELLIOTT
  • NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20210188840
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoinmmune disorders.
    Type: Application
    Filed: July 4, 2018
    Publication date: June 24, 2021
    Inventors: George HYND, Calum MACLEOD, Samuel Edward MANN, Janusz Jozef KULAGOWSKI, Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Gerhard Max GROSS, Edgar JACOBY, Lieven MEERPOEL
  • 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
    Patent number: 11001569
    Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as a cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: May 11, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
  • NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20210087182
    Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: January 20, 2017
    Publication date: March 25, 2021
    Inventors: Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Gerhard Max GROSS, Edgar JACOBY, Lieven MEERPOEL, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Simon Richard GREEN, George HYND
  • CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS
    Publication number: 20210032267
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: February 6, 2020
    Publication date: February 4, 2021
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Benzoxazepin oxazolidinone compounds and methods of use
    Patent number: 10851091
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: December 1, 2020
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum Macleod, Richard Elliott
  • FUSED THIOPHENE DERIVATIVES AND THEIR USES
    Publication number: 20200369682
    Abstract: The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Application
    Filed: February 8, 2019
    Publication date: November 26, 2020
    Inventors: ERIC MELDRUM, BENOÎT DE CHASSEY, PETER MACHIN, ROBERTA LANARO, CALUM MACLEOD, KARINE FABIENNE MALAGU, NICOLAS PROISY, DAVID RICHARD VESEY, PAUL COLIN MICHAEL WINSHIP, MARK CHAMBERS, JEAN-LAURENT PAPARIN
  • FUSED THIOPHENE DERIVATIVES AND THEIR USES
    Publication number: 20200361924
    Abstract: The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
    Type: Application
    Filed: February 8, 2019
    Publication date: November 19, 2020
    Inventors: ERIC MELDRUM, BENOÎT DE CHASSEY, PETER MACHIN, ROBERTA LANARO, CALUM MACLEOD, KARINE FABIENNE MALAGU, NICOLAS PROISY, DAVID RICHARD VESEY, PAUL COLIN MICHAEL WINSHIP, MARK CHAMBERS
  • Pyrazolopyrimidine derivatives as NIK inhibitors
    Patent number: 10822342
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: November 3, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: George Hynd, Patrizia Tisselli, Calum MacLeod, Samuel Edward Mann, Terry Aaron Panchal, John Gary Montana, Stephen Colin Price